CCRM works closely with academic institutions and inventors to accelerate the commercialization of promising early-stage regenerative medicine research. To achieve this, we have developed a model for creating and incubating new companies that we believe improves the chances of their long-term success.
We first identify opportunities by matching technologies with patient and market needs. Programs are then taken from concept to spin-out by strategically leveraging CCRM’s expertise and infrastructure.

 

Our activities include technology sourcing and evaluation; intellectual property management; company concept generation; proof of concept study planning and execution; designing and implementing scalable and regulatory compliant manufacturing processes; leadership placements; and, fundraising. If required, CCRM is then able to provide post-incubation services that support the continued growth and success of these companies.

 

Our 5-step incubation program process:

1. Develop positioning and establish clinical unmet need

2. De-risk technology using desk and lab-based diligence activities

3. Implement scalable, regulatory-compliant manufacturing processes

4. Engage networks for follow-on investment and/or strategic partnerships

5. Provide valuable post-incubation services

 

Our incubation process starts by collaborating with academics to identify promising discoveries and technologies from their labs, assessing how CCRM’s ideas and innovations can provide value, and assisting in filing intellectual property (IP). Then, to generate and create companies, we ideate about company creation, determine how to bundle technologies and conduct internal development. A business plan is created and key opinion leaders (KOLs) are consulted. If required, technologies are bundled, in collaboration with external ventures, strategic partners and/or academic inventions.

Companies are incubated and grown by validating technology, developing manufacturing processes, manufacturing product, seeking strategic partnerships and investment, etc. This process results in a new regenerative medicine, or cell or gene therapy, venture.

CCRM provides support to ventures that graduate this process, building value post-transaction. Types of support include:

  • People: Staff exit with company, regulatory and IT support, technical expertise, finance and back office.
  • Facilities: Development lab access, process development, cGMP facility access, office space.
  • Funding: Preferred rates, seed capital, access to investor network.